• The MK-3281 presentation at AASLD last fall noted that one patient in the phase-1 trial discontinued treatment for severe myoclonus that was judged to be “possibly drug-related” (#msg-42093301).
I consider this info material insofar as I had previously expected MRK to run its own all-oral HCV trial of Boceprevir + MK-3281. Now, MRK will have to look elsewhere if it wants to jump on the all-oral HCV bandwagon.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.